长链非编码 RNA NORAD 作为实体瘤淋巴结转移和预后的新型预测因子：系统评价和荟萃分析。

LncRNA NORAD as a Novel Predictor of Lymph Node Metastasis and Prognosis in Solid Tumors: A Systematic Review and Meta-Analysis.

机构信息

Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.

出版信息

Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820963586. doi: 10.1177/1533033820963586.

BACKGROUND

Non-coding RNA-activated by DNA damage (NORAD), a novel identified lncRNA, was found to be aberrantly expressed in various types of cancer. This meta-analysis was performed to evaluate the value of lncRNA NORAD as a prognostic biomarker in human cancers.

METHODS

We searched PubMed, Web of Science, PMC, and Embase databases thoroughly for eligible literatures. Studies which explored the relationship of lncRNA NORAD expression with clinical outcomes in human cancers were included in our meta-analysis. Review Manager version 5.3 and Stata SE 12.0 were used to perform the data analyses.

RESULTS

Our meta-analysis results indicated that cancer patients with high lncRNA NORAD expression tended to have unfavorable overall survival (OS) (HR = 1.67; 95% CI, 1.44-1.95; P < 0.00001). Moreover, elevated lncRNA NORAD expression showed a significant relationship with poor tumor grade (OR = 1.61; 95% CI, 1.01-2.56; P = 0.05) and more lymph node metastasis (LNM) (OR = 2.66; 95% CI, 1.60-4.43; P = 0.0002).

CONCLUSIONS

LncRNA NORAD could serve as a valuable biomarker to predict poor prognosis and LNM in various human tumors.

背景

DNA 损伤激活的非编码 RNA（NORAD）是一种新发现的长链非编码 RNA（lncRNA），在多种类型的癌症中存在异常表达。本荟萃分析旨在评估 lncRNA NORAD 作为人类癌症预后生物标志物的价值。

方法

我们全面检索了 PubMed、Web of Science、PMC 和 Embase 数据库中的相关文献。纳入探讨 lncRNA NORAD 表达与人类癌症临床结局之间关系的研究进行荟萃分析。使用 Review Manager 版本 5.3 和 Stata SE 12.0 进行数据分析。

结果

荟萃分析结果表明，lncRNA NORAD 高表达的癌症患者总生存期（OS）较差（HR = 1.67；95%CI，1.44-1.95；P < 0.00001）。此外，lncRNA NORAD 高表达与肿瘤分级较差（OR = 1.61；95%CI，1.01-2.56；P = 0.05）和更多淋巴结转移（LNM）（OR = 2.66；95%CI，1.60-4.43；P = 0.0002）显著相关。